1
|
Association with proteasome determines pathogenic threshold of polyglutamine expansion diseases. Biochem Biophys Res Commun 2020; 536:95-99. [PMID: 33370719 DOI: 10.1016/j.bbrc.2020.12.065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 12/18/2020] [Indexed: 11/21/2022]
Abstract
Expansion of glutamine residue track (polyQ) within soluble protein is responsible for eight autosomal-dominant genetic neurodegenerative disorders. These disorders affect cerebellum, striatum, basal ganglia and other brain regions. Each disease develops when polyQ expansion exceeds a pathogenic threshold (Qth). A pathogenic threshold is unique for each disease but the reasons for variability in Qth within this family of proteins are poorly understood. In the previous publication we proposed that polarity of the regions flanking polyQ track in each protein plays a key role in defining Qth value [1]. To explain the correlation between the polarity of the flanking sequences and Qth we performed quantitative analysis of interactions between polyQ-expanded proteins and proteasome. Based on structural and theoretical modeling, we predict that Qth value is determined by the energy of polar interaction of the flanking regions with the polyQ and proteasome. More polar flanking regions facilitate unfolding of α-helical polyQ conformation adopted inside the proteasome and as a result, increase Qth. Predictions of our model are consistent with Qth values observed in clinic for each of the eight polyQ-expansion disorders. Our results suggest that the agents that can destabilize polyQ α-helical structure may have a beneficial therapeutic effect for treatment of polyQ-expansion disorders.
Collapse
|
2
|
Belogurov A, Kuzina E, Kudriaeva A, Kononikhin A, Kovalchuk S, Surina Y, Smirnov I, Lomakin Y, Bacheva A, Stepanov A, Karpova Y, Lyupina Y, Kharybin O, Melamed D, Ponomarenko N, Sharova N, Nikolaev E, Gabibov A. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J 2015; 29:1901-13. [PMID: 25634956 PMCID: PMC4415016 DOI: 10.1096/fj.14-259333] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 12/22/2014] [Indexed: 11/18/2022]
Abstract
Recent findings indicate that the ubiquitin–proteasome system is involved in the pathogenesis of cancer as well as autoimmune and several neurodegenerative diseases, and is thus a target for novel therapeutics. One disease that is related to aberrant protein degradation is multiple sclerosis, an autoimmune disorder involving the processing and presentation of myelin autoantigens that leads to the destruction of axons. Here, we show that brain-derived proteasomes from SJL mice with experimental autoimmune encephalomyelitis (EAE) in an ubiquitin-independent manner generate significantly increased amounts of myelin basic protein peptides that induces cytotoxic lymphocytes to target mature oligodendrocytes ex vivo. Ten times enhanced release of immunogenic peptides by cerebral proteasomes from EAE-SJL mice is caused by a dramatic shift in the balance between constitutive and β1ihigh immunoproteasomes in the CNS of SJL mice with EAE. We found that during EAE, β1i is increased in resident CNS cells, whereas β5i is imported by infiltrating lymphocytes through the blood–brain barrier. Peptidyl epoxyketone specifically inhibits brain-derived β1ihigh immunoproteasomes in vitro (kobs/[I] = 240 M−1s−1), and at a dose of 0.5 mg/kg, it ameliorates ongoing EAE in vivo. Therefore, our findings provide novel insights into myelin metabolism in pathophysiologic conditions and reveal that the β1i subunit of the immunoproteasome is a potential target to treat autoimmune neurologic diseases.—Belogurov Jr., A., Kuzina, E., Kudriaeva, A., Kononikhin, A., Kovalchuk, S., Surina, Y., Smirnov, I., Lomakin, Y., Bacheva, A., Stepanov, A., Karpova, Y., Lyupina, Y., Kharybin, O., Melamed, D., Ponomarenko, N., Sharova, N., Nikolaev, E., Gabibov, A. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity.
Collapse
Affiliation(s)
- Alexey Belogurov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Ekaterina Kuzina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Anna Kudriaeva
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexey Kononikhin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Sergey Kovalchuk
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yelena Surina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Ivan Smirnov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yakov Lomakin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Anna Bacheva
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexey Stepanov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yaroslava Karpova
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yulia Lyupina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Oleg Kharybin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Dobroslav Melamed
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Natalia Ponomarenko
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Natalia Sharova
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Eugene Nikolaev
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexander Gabibov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| |
Collapse
|
3
|
Niewerth D, van Meerloo J, Jansen G, Assaraf YG, Hendrickx TC, Kirk CJ, Anderl JL, Zweegman S, Kaspers GJL, Cloos J. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. Biochem Pharmacol 2014; 89:43-51. [PMID: 24552657 DOI: 10.1016/j.bcp.2014.02.005] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2014] [Revised: 02/06/2014] [Accepted: 02/07/2014] [Indexed: 12/22/2022]
Abstract
PR-924 is a novel prototypic immunoproteasome inhibitor bearing markedly enhanced specificity for the β5i immunoproteasome subunit, compared to the classical proteasome inhibitor bortezomib. Here, we assessed the growth inhibitory potential of PR-924 in three human hematologic malignancy cell lines (CCRF-CEM, THP1, and 8226) and their bortezomib-resistant sublines. Parental cells displayed equal sensitivity to PR-924 (IC₅₀: 1.5-2.8 μM), whereas their bortezomib-resistant tumor lines displayed a 10-12 fold cross-resistance to PR-924. However, PR-924 cross-resistance factors for bortezomib-resistant sublines were markedly lower compared to the resistance factors to bortezomib. Proteasome inhibition experiments confirmed that PR-924 specifically inhibited β5i activity, even far below concentrations that exerted anti-proliferative activity. We further determined whether PR-924 activity might be compromised by acquisition of drug resistance phenomena. Indeed, CEM cells rendered stepwise resistant to 20 μM PR-924 (CEM/PR20) displayed 13-fold PR-924-resistance and 10-fold cross-resistance to bortezomib. CEM/PR20 cells were devoid of mutations in the PSMB8 gene (encoding β5i), but acquired Met45Ile mutation in the PSMB5 gene (encoding constitutive β5), consistent with β5 mutations observed in bortezomib-resistant cells. Furthermore, compared to parental CEM cells, CEM/PR20 cells exhibited 2.5-fold upregulation of constitutive proteasome subunit expression, whereas immunoproteasome subunit expression was 2-fold decreased. In conclusion, PR-924 displayed potent anti-leukemic activity including toward bortezomib-resistant leukemia cells. Despite the specificity of PR-924 to the β5i immunoproteasome subunit, its anti-leukemic effect required concentrations that blocked both β5 and β5i subunits. This is underscored by the emergence of mutations in PSMB5 rather than in PSMB8.
Collapse
Affiliation(s)
- Denise Niewerth
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands.
| | - Johan van Meerloo
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
| | - Gerrit Jansen
- Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands.
| | - Yehuda G Assaraf
- The Fred Wyszkowski Cancer Research Lab, Technion-Israel Institute of Technology, Haifa, Israel.
| | - Tessa C Hendrickx
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands.
| | - Christopher J Kirk
- Research Department, Onyx Pharmaceuticals Inc., South San Francisco, CA, USA.
| | - Janet L Anderl
- Research Department, Onyx Pharmaceuticals Inc., South San Francisco, CA, USA.
| | - Sonja Zweegman
- Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
| | - Gertjan J L Kaspers
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands.
| | - Jacqueline Cloos
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
| |
Collapse
|
4
|
Niewerth D, Kaspers GJL, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, van de Ven PM, Zweegman S, Jansen G, Cloos J. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol 2014; 7:7. [PMID: 24418325 PMCID: PMC3896789 DOI: 10.1186/1756-8722-7-7] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Accepted: 01/06/2014] [Indexed: 11/17/2022] Open
Abstract
Background Despite encouraging results with the proteasome inhibitor bortezomib in the treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence calling for novel strategies to overcome bortezomib-resistance. We previously showed that bortezomib-resistant human leukemia cell lines expressed significantly lower levels of immunoproteasome at the expense of constitutive proteasomes, which harbored point mutations in exon 2 of the PSMB5 gene encoding the β5 subunit. Here we investigated whether up-regulation of immunoproteasomes by exposure to interferon-γ restores sensitivity to bortezomib in myeloma and leukemia cell lines with acquired resistance to bortezomib. Methods RPMI-8226 myeloma, THP1 monocytic/macrophage and CCRF-CEM (T) parental cells and sub lines with acquired resistance to bortezomib were exposed to Interferon-γ for 24-48 h where after the effects on proteasome subunit expression and activity were measured, next to sensitivity measurements to proteasome inhibitors bortezomib, carfilzomib, and the immunoproteasome selective inhibitor ONX 0914. At last, siRNA knockdown experiments of β5i and β1i were performed to identify the contribution of these subunits to sensitivity to proteasome inhibition. Statistical significance of the differences were determined using the Mann-Whitney U test. Results Interferon-γ exposure markedly increased immunoproteasome subunit mRNA to a significantly higher level in bortezomib-resistant cells (up to 30-fold, 10-fold, and 6-fold, in β1i, β5i, and β2i, respectively) than in parental cells. These increases were paralleled by elevated immunoproteasome protein levels and catalytic activity, as well as HLA class-I. Moreover, interferon-γ exposure reinforced sensitization of bortezomib-resistant tumor cells to bortezomib and carfilzomib, but most prominently to ONX 0914, as confirmed by cell growth inhibition studies, proteasome inhibitor-induced apoptosis, activation of PARP cleavage and accumulation of polyubiquitinated proteins. This sensitization was abrogated by siRNA silencing of β5i but not by β1i silencing, prior to pulse exposure to interferon-γ. Conclusion Downregulation of β5i subunit expression is a major determinant in acquisition of bortezomib-resistance and enhancement of its proteasomal assembly after induction by interferon-γ facilitates restoration of sensitivity in bortezomib-resistant leukemia cells towards bortezomib and next generation (immuno) proteasome inhibitors.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Jacqueline Cloos
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands.
| |
Collapse
|
5
|
Klinger PP, Schubert U. The ubiquitin–proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Rev Anti Infect Ther 2014; 3:61-79. [PMID: 15757458 DOI: 10.1586/14787210.3.1.61] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Since the discovery of HIV approximately 20 years ago, more than 60 million individuals have been infected, and AIDS still remains one of the most devastating diseases humankind has ever faced. Unfortunately, there is little hope that an effective vaccine will be developed in the near future. Current antiretroviral treatment is based on drugs that either target the viral enzymes (protease and reverse transcriptase) or the attachment and entry of the virus. Although the introduction of highly active antiretroviral therapy in the mid-1990s has led to a profound reduction in HIV-related morbidity and mortality, the complete eradication of the virus from infected individuals has never been achieved. In addition, these antiviral drugs can induce serious adverse effects, particularly when administered in combination over prolonged treatment periods. A further drawback to these treatments is that with the high mutation rate of HIV, drug-resistant mutants are evolving, particularly when antiretroviral treatment only suppresses virus replication to marginal levels in latently infected cells making up the virus reservoirs in vivo. Cellular genes have much lower mutation rates, and drug-mediated modulation of specific cellular pathways represents an attractive antiviral strategy. Recent findings showing that proteasome inhibitors interfere with budding, maturation and infectivity of HIV have triggered intensive investigation of the hitherto unappreciated function of the ubiquitin-proteasome system in HIV replication. It was also observed that, like several other retroviruses, HIV-1 virions contain a small amount of mono-ubiquitinylated Gag proteins. Currently, two E3-type ubiquitin ligases, in addition to one E3-like protein, have been identified as regulators of HIV budding. These ligases might represent interesting targets for therapeutic intervention.
Collapse
Affiliation(s)
- Patricia P Klinger
- University of Erlangen-Nuremberg, Institute of Clinical and Molecular Virology, Schlossgarten 4, 91054 Erlangen, Germany
| | | |
Collapse
|
6
|
Woelk CH, Zhang JX, Walls L, Viriyakosol S, Singhania A, Kirkland TN, Fierer J. Factors regulated by interferon gamma and hypoxia-inducible factor 1A contribute to responses that protect mice from Coccidioides immitis infection. BMC Microbiol 2012; 12:218. [PMID: 23006927 PMCID: PMC3528620 DOI: 10.1186/1471-2180-12-218] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2012] [Accepted: 07/20/2012] [Indexed: 01/05/2023] Open
Abstract
Background Coccidioidomycosis results from airborne infections caused by either Coccidioides immitis or
C. posadasii. Both are pathogenic fungi that live in desert soil in the New World and can infect normal hosts, but most infections are self-limited. Disseminated infections occur in approximately 5% of cases and may prove fatal. Mouse models of the disease have identified strains that are resistant (e.g. DBA/2) or susceptible (e.g. C57BL/6) to these pathogens. However, the genetic and immunological basis for this difference has not been fully characterized. Results Microarray technology was used to identify genes that were differentially expressed in lung tissue between resistant DBA/2 and sensitive C57BL/6 mice after infection with C. immitis. Differentially expressed genes were mapped onto biological pathways, gene ontologies, and protein interaction networks, which revealed that innate immune responses mediated by Type II interferon (i.e., IFNG) and the signal transducer and activator of transcription 1 (STAT1) contribute to the resistant phenotype. In addition, upregulation of hypoxia inducible factor 1A (HIF1A), possibly as part of a larger inflammatory response mediated by tumor necrosis factor alpha (TNFA), may also contribute to resistance. Microarray gene expression was confirmed by real-time quantitative PCR for a subset of
12 genes, which revealed that IFNG HIF1A and TNFA, among others, were significantly differentially expressed between the two strains at day 14 post-infection. Conclusion These results confirm the finding that DBA/2 mice express more Type II interferon and interferon stimulated genes than genetically susceptible strains and suggest that differential expression of HIF1A may also play a role in protection.
Collapse
Affiliation(s)
- Christopher H Woelk
- Veterans Affairs San Diego Healthcare System, Mail Code 9111-F, San Diego, California 92161, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Basler M, Lauer C, Moebius J, Weber R, Przybylski M, Kisselev AF, Tsu C, Groettrup M. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. THE JOURNAL OF IMMUNOLOGY 2012; 189:1868-77. [PMID: 22772448 DOI: 10.4049/jimmunol.1103592] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The proteasome is responsible for the generation of most epitopes presented on MHC class I molecules. Treatment of cells with IFN-γ leads to the replacement of the constitutive catalytic subunits β1, β2, and β5 by the inducible subunits low molecular mass polypeptide (LMP) 2 (β1i), multicatalytic endopeptidase complex-like-1 (β2i), and LMP7 (β5i), respectively. The incorporation of these subunits is required for the production of numerous MHC class I-restricted T cell epitopes. The structural features rather than the proteolytic activity of an immunoproteasome subunit are needed for the generation of some epitopes, but the underlying mechanisms have remained elusive. Experiments with LMP2-deficient splenocytes revealed that the generation of the male HY-derived CTL-epitope UTY(246-254) was dependent on LMP2. Treatment of male splenocytes with an LMP2-selective inhibitor did not reduce UTY(246-254) presentation, whereas silencing of β1 activity increased presentation of UTY(246-254). In vitro degradation experiments showed that the caspase-like activity of β1 was responsible for the destruction of this CTL epitope, whereas it was preserved when LMP2 replaced β1. Moreover, inhibition of the β5 subunit rescued the presentation of the influenza matrix 58-66 epitope, thus suggesting that a similar mechanism can apply to the exchange of β5 by LMP7. Taken together, our data provide a rationale why the structural property of an immunoproteasome subunit rather than its activity is required for the generation of a CTL epitope.
Collapse
Affiliation(s)
- Michael Basler
- Biotechnology Institute Thurgau, Constance University, CH-8280 Kreuzlingen, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Camargo ACM, Fernandes BL, Cruz L, Ferro ES. Bioactive Peptides Produced by Limited Proteolysis. ACTA ACUST UNITED AC 2012. [DOI: 10.4199/c00056ed1v01y201204npe002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
9
|
The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci 2011; 68:1491-502. [PMID: 21387144 PMCID: PMC3071949 DOI: 10.1007/s00018-011-0657-y] [Citation(s) in RCA: 186] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Revised: 02/17/2011] [Accepted: 02/18/2011] [Indexed: 02/07/2023]
Abstract
The ubiquitin–proteasome system (UPS) degrades intracellular proteins into peptide fragments that can be presented by major histocompatibility complex (MHC) class I molecules. While the UPS is functional in all mammalian cells, its subunit composition differs depending on cell type and stimuli received. Thus, cells of the hematopoietic lineage and cells exposed to (pro)inflammatory cytokines express three proteasome immunosubunits, which form the catalytic centers of immunoproteasomes, and the proteasome activator PA28. Cortical thymic epithelial cells express a thymus-specific proteasome subunit that induces the assembly of thymoproteasomes. We here review new developments regarding the role of these different proteasome components in MHC class I antigen processing, T cell repertoire selection and CD8 T cell responses. We further discuss recently discovered functions of proteasomes in peptide splicing, lymphocyte survival and the regulation of cytokine production and inflammatory responses.
Collapse
|
10
|
Bergeron M, Blanchette J, Rouleau P, Olivier M. Abnormal IFN-gamma-dependent immunoproteasome modulation by Trypanosoma cruzi-infected macrophages. Parasite Immunol 2008; 30:280-92. [PMID: 18312504 DOI: 10.1111/j.1365-3024.2008.01022.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Proteasomes are the main producers of Ag loaded onto MHC class I molecules. Following IFN-gamma stimulation however, the constitutive subunits of the proteasome are replaced by the immunosubunits low molecular weight protein 2 (LMP2), multicatalytic endopeptidase complex-like 1 and low molecular weight protein 7 (LMP7), which generally heighten the immunogenecity of proteasome generated epitopes. Given that Trypanosoma cruzi, the aetiological agent of Chagas' disease, elicits a T(helper)1 response from its host if the infection is to be contained, the aim of this study was to verify whether this parasite modulates J774 and B10R mouse macrophage (MuPhi) immunoproteasome subunit and MHC class I expressions and, if so, identify the mechanism(s) responsible for that modulation. Results show that T. cruzi infection of mouse MuPhi reduces IFN-gamma-mediated immunoproteasome synthesis, along with MHC class I mRNA synthesis and cell surface expression. The infection by T. cruzi induces the release of reactive oxygen species (ROS) from MuPhi, and those ROS significantly inhibit protein tyrosine phosphatase activity, thereby leading to the activation of the SAPK/JNK signalling pathway, which is responsible for the observed IFN-gamma-mediated immunoproteasome synthesis and MHC class I down-regulation. To our knowledge, this is the first report that specifically identifies a mechanism by which a pathogen achieves immunoproteasome down-modulation.
Collapse
Affiliation(s)
- M Bergeron
- Centre de recherche en infectiologie, Centre hospitalier universitaire de Québec, Pavillon CHUL, Québec, Canada
| | | | | | | |
Collapse
|
11
|
Ciccaglione AR, Stellacci E, Marcantonio C, Muto V, Equestre M, Marsili G, Rapicetta M, Battistini A. Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol 2006; 81:202-14. [PMID: 17050603 PMCID: PMC1797261 DOI: 10.1128/jvi.01011-06] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Hepatitis C virus (HCV) proteins are known to interfere at several levels with both innate and adaptive responses of the host. A key target in these effects is the interferon (IFN) signaling pathway. While the effects of nonstructural proteins are well established, the role of structural proteins remains controversial. We investigated the effect of HCV structural proteins on the expression of interferon regulatory factor 1 (IRF-1), a secondary transcription factor of the IFN system responsible for inducing several key antiviral and immunomodulatory genes. We found substantial inhibition of IRF-1 expression in cells expressing the entire HCV replicon. Suppression of IRF-1 synthesis was mainly mediated by the core structural protein and occurred at the transcriptional level. The core protein in turn exerted a transcriptional repression of several interferon-stimulated genes, targets of IRF-1, including interleukin-15 (IL-15), IL-12, and low-molecular-mass polypeptide 2. These data recapitulate in a unifying mechanism, i.e., repression of IRF-1 expression, many previously described pathogenetic effects of HCV core protein and suggest that HCV core-induced IRF-1 repression may play a pivotal role in establishing persistent infection by dampening an effective immune response.
Collapse
Affiliation(s)
- Anna R Ciccaglione
- Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 Rome 00161, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Remoli A, Marsili G, Perrotti E, Gallerani E, Ilari R, Nappi F, Cafaro A, Ensoli B, Gavioli R, Battistini A. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 2006; 396:371-80. [PMID: 16512786 PMCID: PMC1462712 DOI: 10.1042/bj20051570] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The Tat protein is the transcriptional activator of HIV-1 gene expression, which is not only essential for viral replication, but also important in the complex HIV-induced pathogenesis of AIDS, as both an intracellular and an extracellular released protein. Accordingly, Tat is able to profoundly affect cellular gene expression, regulating several cellular functions, also in non-infected cells. We showed recently that Tat induces modification of immunoproteasomes in that it up-regulates LMP7 (low-molecular-mass polypeptide 7) and MECL1 (multicatalytic endopeptidase complex-like 1) subunits and down-modulates the LMP2 subunit, resulting in a change in the generation and presentation of epitopes in the context of MHC class I. In particular, Tat increases presentation of subdominant and cryptic epitopes. In the present study, we investigated the molecular mechanism responsible for the Tat-induced LMP2 down-regulation and show that intracellular Tat represses transcription of the LMP2 gene by competing with STAT1 (signal transducer and activator of transcription 1) for binding to IRF-1 (interferon-regulatory factor-1) on the overlapping ICS-2 (interferon consensus sequence-2)-GAS (gamma-interferon-activated sequence) present in the LMP2 promoter. This element is constitutively occupied in vivo by the unphosphorylated STAT1-IRF-1 complex, which is responsible for the basal transcription of the gene. Sequestration of IRF-1 by intracellular Tat impairs the formation of the complex resulting in lower LMP2 gene transcription and LMP2 protein expression, which is associated with increased proteolytic activity. On the other hand, extracellular Tat induces the expression of LMP2. These effects of Tat provide another effective mechanism by which HIV-1 affects antigen presentation in the context of the MHC class I complex and may have important implications in the use of Tat for vaccination strategies.
Collapse
Affiliation(s)
- Anna L. Remoli
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
| | - Giulia Marsili
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
| | - Edvige Perrotti
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
| | - Eleonora Gallerani
- †Department of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy
| | - Ramona Ilari
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
| | - Filomena Nappi
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
| | - Aurelio Cafaro
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
| | - Barbara Ensoli
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
| | - Riccardo Gavioli
- †Department of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy
| | - Angela Battistini
- *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, 299 – Rome 00161, Italy
- To whom correspondence should be addressed (email )
| |
Collapse
|
13
|
Strehl B, Seifert U, Krüger E, Heink S, Kuckelkorn U, Kloetzel PM. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 2005; 207:19-30. [PMID: 16181324 DOI: 10.1111/j.0105-2896.2005.00308.x] [Citation(s) in RCA: 176] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The proteasome system is a central component of a cascade of proteolytic processing steps required to generate antigenic peptides presented at the cell surface to cytotoxic T lymphocytes by major histocompatibility complex (MHC) class I molecules. The nascent protein pool or DRiPs (defective ribosomal products) appear to represent an important source for MHC class I epitopes. Owing to the destructive activities of aminopeptidases in the cytosol, at most 1% of the peptides generated by the ubiquitin-proteasome system seems to be made available to the immune system. Interferon-gamma (IFN-gamma) helps to override these limitations by the formation of immunoproteasomes, the activator complex PA28, and the induction of several aminopeptidases. Both immunoproteasomes and PA28 use cleavage sites already used by constitutive proteasomes but with altered and in some cases dramatically enhanced frequency. Therefore, two proteolytic cascades appear to have evolved to provide MHC class I epitopes. The 'constitutive proteolytic cascade' is designed to efficiently degrade proteins to single amino acid residues, allowing only a small percentage of peptides to be presented at the cell surface. In contrast, the IFN-gamma-controlled proteolytic cascade generates larger amounts of appropriate antigenic peptides, assuring more peptides to overcome the proteolytic restrictions of the constitutive system, thereby enhancing MHC class I antigen presentation.
Collapse
Affiliation(s)
- Britta Strehl
- Institut für Biochemie, Charité, Berlin University Berlin, Germany
| | | | | | | | | | | |
Collapse
|
14
|
Kloetzel PM. The proteasome and MHC class I antigen processing. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2005; 1695:225-33. [PMID: 15571818 DOI: 10.1016/j.bbamcr.2004.10.004] [Citation(s) in RCA: 134] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
By generating peptides from intracellular antigens, which are then presented to T cells, the ubiquitin/26S proteasome system plays a central role in the cellular immune response. Under the control of interferon-gamma the proteolytic properties of the proteasome are adapted to the requirements of the immune system. Interferon-gamma induces the formation of immunoproteasomes and the synthesis of the proteasome activator PA28. Both alter the proteolytic properties of the proteasome complex and enhance proteasomal function in antigen presentation. Thus, a combination of several of regulatory events tunes the proteasome system for maximal efficiency in the generation of MHC class I antigens.
Collapse
Affiliation(s)
- Peter-M Kloetzel
- Institut für Biochemie, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin, Monbijoust.2, 10117 Berlin, Germany.
| |
Collapse
|
15
|
Krüger E, Kuckelkorn U, Sijts A, Kloetzel PM. The components of the proteasome system and their role in MHC class I antigen processing. Rev Physiol Biochem Pharmacol 2004; 148:81-104. [PMID: 12687403 DOI: 10.1007/s10254-003-0010-4] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
By generating peptides from intracellular antigens which are then presented to T cells, the ubiquitin/26S proteasome system plays a central role in the cellular immune response. The proteolytic properties of the proteasome are adapted to the requirements of the immune system by proteasome components whose synthesis is under the control of interferon-gamma. Among these are three subunits with catalytic sites that are incorporated into the enzyme complex during its de novo synthesis. Thus, the proteasome assembly pathway and the formation of immunoproteasomes play a critical regulatory role in the regulation of the proteasome's catalytic properties. In addition, interferon-gamma also induces the synthesis of the proteasome activator PA28 which, as part of the so-called hybrid proteasome, exerts a more selective function in antigen presentation. Consequently, the combination of a number of regulatory events tunes the proteasome system to gain maximal efficiency in the generation of peptides with regard to their quality and quantity.
Collapse
Affiliation(s)
- E Krüger
- Institut für Biochemie, Medizinische Fakultät, Humboldt-Universität zu Berlin, Charité, Monbijoust 2, 10117 Berlin, Germany
| | | | | | | |
Collapse
|
16
|
Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 2002; 80:1-70. [PMID: 12078479 DOI: 10.1016/s0065-2776(02)80012-8] [Citation(s) in RCA: 271] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Over the past decade there has been considerable progress in understanding how MHC class I-presented peptides are generated. The emerging theme is that the immune system has not evolved its own specialized proteolytic mechanisms but instead utilizes the phylogenetically ancient catabolic pathways that continually turnover proteins in all cells. Three distinct proteolytic steps have now been defined in MHC class I antigen presentation. The first step is the degradation of proteins by the ubiquitin-proteasome pathway into oligopeptides that either are of the correct size for presentation or are extended on their amino-termini. In the second step, aminopeptidases trim N-extended precursors into peptides of the correct length to be presented on class I molecules. The third step involves the destruction of peptides by endo- and exopeptidases, which limits antigen presentation, but is important for preventing the accumulation of peptides and recycling them back to amino acids for protein synthesis or production of energy. The immune system has evolved several components that modify the activity of these ancient pathways in ways that enhance the generation of class I-presented peptides. These include catalytically active subunits of the proteasome, the PA28 proteasome activator, and leucine aminopeptidase, all of which are upregulated by interferon-gamma. In addition to these pathways that operate in all cells, dendritic cells and macrophages can also generate class I-presented peptides from proteins internalized from the extracellular fluids by degrading them in endocytic compartments or transferring them to the cyotosol for degradation by proteasomes.
Collapse
Affiliation(s)
- Kenneth L Rock
- Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
| | | | | | | |
Collapse
|
17
|
Gavioli R, Vertuani S, Masucci MG. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors. Int J Cancer 2002; 101:532-8. [PMID: 12237893 DOI: 10.1002/ijc.10653] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
EBV-infected cells and EBV-associated tumors may evade CTL recognition by defective antigen processing, resulting in poor presentation of CTL epitopes. Since the proteasome is the major source of MHC class I-presented peptides, we analyzed the effect of proteasome inhibitors on the expression of surface HLA class I and the generation of EBV-derived CTL epitopes presented by the HLA-A2 and HLA-A11 alleles. Treatment with covalent and reversible inhibitors of the proteasome partially reduced the total and allele-specific expression of surface HLA class I in EBV-carrying LCLs. HLA-A2 expression was also decreased by treatment with leupeptin and bestatin, while HLA-A11 expression was affected by treatment with phenanthroline. Despite their general inhibitory effect on HLA class I expression, all proteasome inhibitors tested enhanced the presentation of 2 subdominant HLA-A2 epitopes from EBV LMP1 and LMP2, while the presentation of the immunodominant HLA-A11-restricted epitope from EBNA4 was inhibited by MG132 and lactacystin and increased by ZL(3)VS. Treatment with ZL(3)VS restored the presentation of endogenously expressed EBNA4 in 1 HLA-A11-positive BL cell line. These findings suggest that specific inhibitors of the proteasome may be used to increase the antigenicity of virus-infected and malignant cells that are per se inefficient at generating particular CTL target epitopes.
Collapse
Affiliation(s)
- Riccardo Gavioli
- Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden
| | | | | |
Collapse
|
18
|
Grommé M, Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 2002; 39:181-202. [PMID: 12200050 DOI: 10.1016/s0161-5890(02)00101-3] [Citation(s) in RCA: 122] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Major histocompatibility complex (MHC) class I molecules usually present endogenous peptides at the cell surface. This is the result of a cascade of events involving various dedicated proteins like the peptide transporter associated with antigen processing (TAP) and the ER chaperone tapasin. However, alternative ways for class I peptide loading exist which may be highly relevant in a process called cross-priming. Both pathways are described here in detail. One major difference between these pathways is that the proteases involved in the generation of peptides are different. How proteases and peptidases influence peptide generation and degradation will be discussed. These processes determine the amount of peptides available for TAP translocation and class I binding and ultimately the immune response.
Collapse
Affiliation(s)
- Monique Grommé
- Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
| | | |
Collapse
|
19
|
Del-Val M, López D. Multiple proteases process viral antigens for presentation by MHC class I molecules to CD8(+) T lymphocytes. Mol Immunol 2002; 39:235-47. [PMID: 12200053 DOI: 10.1016/s0161-5890(02)00104-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Recognition by CD8(+) cytotoxic T lymphocytes of any intracellular viral protein requires its initial cytosolic proteolytic processing, the translocation of processed peptides to the endoplasmic reticulum via the transporters associated with antigen processing, and their binding to nascent major histocompatibility complex (MHC) class I molecules that then present the antigenic peptides at the infected cell surface. From initial assumptions that the multicatalytic and ubiquitous proteasome is the only protease capable of fully generating peptide ligands for MHC class I molecules, the last few years have seen the identification of a number of alternative proteases that contribute to endogenous antigen processing. Trimming by non-proteasomal proteases of precursor peptides produced by proteasomes is now a well-established fact. In addition, proteases that can process antigens in a fully proteasome-independent fashion have also been identified. The final level of presentation of many viral epitopes is probably the result of interplay between different proteolytic activities. This expands the number of tissues and physiological and pathological situations compatible with antigen presentation, as well as the universe of pathogen-derived sequences available for recognition by CD8(+) T lymphocytes.
Collapse
Affiliation(s)
- Margarita Del-Val
- Centro Nacional de Microbiologi;a, Instituto de Salud Carlos III, Ctra. Pozuelo, Km 2, E-28220 Majadahonda, Madrid, Spain.
| | | |
Collapse
|
20
|
Kessler BM, Glas R, Ploegh HL. MHC class I antigen processing regulated by cytosolic proteolysis-short cuts that alter peptide generation. Mol Immunol 2002; 39:171-9. [PMID: 12200049 DOI: 10.1016/s0161-5890(02)00100-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Cytotoxic T lymphocyte (CTL)-mediated immune responses rely on the efficiency of MHC class I ligand generation and presentation by antigen presenting cells (APCs). Whereas the abnormal expression of MHC molecules and transporters associated with antigen processing (TAPs) are commonly discussed as factors that modulate antigen presentation, much less is known about possible regulatory mechanisms at the level of proteolysis responsible for the generation of antigenic peptides. The ubiquitin-proteasome system is recognized as the major component responsible for this process in the cytosol and its activity can be regulated by cytokines, such as IFN-gamma. However, new evidence suggests the involvement of other proteases that can contribute to cytosolic proteolysis and therefore, to the quality and quantity of antigen production. Here, we review recent findings on an increasing number of proteolytic enzymes linked to antigen presentation, and we discuss how regulation of cytosolic protease activities might have implications for immune escape mechanisms that could be used by tumor cells and pathogens.
Collapse
Affiliation(s)
- Benedikt M Kessler
- Department of Pathology, Harvard Medical School, Room 137, Building D2, 200 Longwood Avenue, Boston, MA 02115, USA
| | | | | |
Collapse
|
21
|
Holtappels R, Thomas D, Podlech J, Reddehase MJ. Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype. J Virol 2002; 76:151-64. [PMID: 11739681 PMCID: PMC135724 DOI: 10.1128/jvi.76.1.151-164.2002] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The importance of CD8 T cells for the control of cytomegalovirus (CMV) infection has raised interest in the identification of immunogenic viral proteins as candidates for vaccination and cytoimmunotherapy. The final aim is to determine the viral "immunome" for any major histocompatibility complex class I molecule by antigenicity screening of proteome-derived peptides. For human CMV, there is a limitation to this approach: the T cells used as responder cells for peptide screening are usually memory cells that have undergone in vivo selection. On this basis, pUL83 (pp65) and pUL123 (IE1 or pp68 to -72) were classified as immunodominant proteins. It is an open question whether this limited "memory immunome" really reflects the immunogenic potential of the human CMV proteome. Here we document an analogous focus of the memory repertoire on two proteins of murine CMV. Specifically, ca. 80% of all memory CD8 T cells in the spleen as well as in persisting pulmonary infiltrates were found to be specific for the known IE1 peptide 168YPHFMPTNL176 and for the peptide 257AGPPRYSRI265, newly defined here, derived from open reading frame m164. Notably, CD8 T-cell lines of both specificities protected against acute infection upon adoptive transfer. In contrast, the natural immune response to acute infection in draining lymph nodes and in the lungs indicated a somewhat broader specificity repertoire. We conclude that the low number of antigenic peptides identified so far for CMVs reflects a focused memory repertoire, and we predict that more antigenic peptides will be disclosed by analysis of the acute immune response.
Collapse
Affiliation(s)
- Rafaela Holtappels
- Institute for Virology, Johannes Gutenberg University, 55101 Mainz, Germany
| | | | | | | |
Collapse
|
22
|
Kuon W, Holzhütter HG, Appel H, Grolms M, Kollnberger S, Traeder A, Henklein P, Weiss E, Thiel A, Lauster R, Bowness P, Radbruch A, Kloetzel PM, Sieper J. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2001; 167:4738-46. [PMID: 11591805 DOI: 10.4049/jimmunol.167.8.4738] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The association of HLA-B27 with ankylosing spondylitis and reactive arthritis is the strongest one known between an MHC class I Ag and a disease. We have searched the proteome of the bacterium Chlamydia trachomatis for HLA-B27 binding peptides that are stimulatory for CD8(+) cells both in a model of HLA-B27 transgenic mice and in patients. This was done by combining two biomathematical computer programs, the first of which predicts HLA-B27 peptide binding epitopes, and the second the probability of HLA-B27 peptide generation by the proteasome system. After preselection, immunodominant peptides were identified by Ag-specific flow cytometry. Using this approach we have identified for the first time nine peptides derived from different C. trachomatis proteins that are stimulatory for CD8(+) T cells. Eight of these nine murine-derived peptides were recognized by cytotoxic T cells. The same strategy was used to identify B27-restricted chlamydial peptides in three patients with reactive arthritis. Eleven peptides were found to be stimulatory for patient-derived CD8(+) T cells, of which eight overlapped those found in mice. Additionally, we applied the tetramer technology, showing that a B27/chlamydial peptide containing one of the chlamydial peptides stained CD8(+) T cells in patients with Chlamydia-induced arthritis. This comprehensive approach offers the possibility of clarifying the pathogenesis of B27-associated diseases.
Collapse
Affiliation(s)
- W Kuon
- Medical Department I, Klinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Groettrup M, Khan S, Schwarz K, Schmidtke G. Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie 2001; 83:367-72. [PMID: 11295499 DOI: 10.1016/s0300-9084(01)01251-2] [Citation(s) in RCA: 109] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
When cells are stimulated with the cytokines IFN-gamma or TNF-alpha, the synthesis of three proteasome subunits LMP2 (beta1i), LMP7 (beta5i), and MECL-1 (beta2i) is induced. These subunits replace the three subunits delta (beta1), MB1 (beta5), and Z (beta2), which bear the catalytically active sites of the proteasome, during proteasome neosynthesis. The cytokine-induced exchanges of three active site subunits of a complex protease is unprecedented in biology and one may expect a strong functional driving force for this system to evolve. These cytokine-induced replacements of proteasome subunits are believed to favour the production of peptide ligands of major histocompatibility complex (MHC) class I molecules for the stimulation of cytotoxic T cells. Although the peptide production by constitutive proteasomes is able to maintain peptide-dependent MHC class I cell surface expression in the absence of LMP2 and LMP7, these subunits were recently shown to be pivotal for the generation or destruction of several unique epitopes. In this review we discuss the recent data on LMP2/LMP7/MECL-1-dependent epitope generation and the functions of each of these subunit exchanges. We propose that these subunit exchanges have evolved not only to optimize class I peptide loading but also to generate LMP2/LMP7/MECL-1-dependent epitopes in inflammatory sites which are not proteolytically generated in uninflamed tissues. This difference in epitope generation may serve to better stimulate T cells in the sites of an ongoing immune response and to avoid autoimmunity in uninflamed tissues.
Collapse
Affiliation(s)
- M Groettrup
- Research Department, Cantonal Hospital St. Gall, 9007, St. Gallen, Switzerland.
| | | | | | | |
Collapse
|
24
|
Abstract
The proteasome is an essential part of our immune surveillance mechanisms: by generating peptides from intracellular antigens it provides peptides that are then 'presented' to T cells. But proteasomes--the waste-disposal units of the cell--typically do not generate peptides for antigen presentation with high efficiency. How, then, does the proteasome adapt to serve the immune system well?
Collapse
Affiliation(s)
- P M Kloetzel
- Institut für Biochemie, Medical Faculty, Charité, Humboldt University, Monbijoustrasse 2, 10117 Berlin, Germany.
| |
Collapse
|
25
|
Dahlmann B, Ruppert T, Kuehn L, Merforth S, Kloetzel PM. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 2000; 303:643-53. [PMID: 11061965 DOI: 10.1006/jmbi.2000.4185] [Citation(s) in RCA: 166] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
It is concluded from many experiments that mammalian tissues and cells must contain a heterogeneous population of 20 S proteasome complexes. We describe the purification and separation by chromatographic procedures of constitutive 20 S proteasomes, 20 S immuno-proteasomes and intermediate-type 20 S proteasomes from a given tissue. Our data demonstrate that each of these three groups comprises more than one subtype and that the relative ratios of the subtypes differ between different rat tissues. Thus, six subtypes could be identified in rat muscle tissue. Subtypes I and II are constitutive proteasomes, while subtypes V and VI comprise immuno-proteasomes. Subtypes III and IV belong to a group of intermediate-type proteasomes. The subtypes differ with regard to their enzymatic characteristics. Subtypes I-III exhibit high chymotrypsin-like activity and high peptidylglutamylpeptide hydrolysing activity, while these activities are depressed in subtypes IV-VI. In contrast, trypsin-like activity of subtypes IV-VI is enhanced in comparison to subtypes I-III. Importantly, the subtypes also differ in their preferential cleavage site usage when tested by digestion of a synthetic 25mer polypeptide substrate. Therefore, the characteristics of proteasomes purified from tissues or cells represent the average of the different subtype activities which in turn may have different functions in vivo.
Collapse
Affiliation(s)
- B Dahlmann
- Department of Clinical Biochemistry, Deutsches Diabetes-Forschungsinstitut, Düsseldorf, Germany.
| | | | | | | | | |
Collapse
|
26
|
Schmidtke G, Emch S, Groettrup M, Holzhutter HG. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome. J Biol Chem 2000; 275:22056-63. [PMID: 10806206 DOI: 10.1074/jbc.m002513200] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The 20 S proteasome is an endoprotease complex that preferentially cleaves peptides C-terminal of hydrophobic, basic, and acidic residues. Recently, we showed that these specific activities, classified as chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide-hydrolyzing (PGPH) activity, are differently affected by Ritonavir, an inhibitor of human immunodeficiency virus-1 protease. Ritonavir competitively inhibited the chymotrypsin-like activity, whereas the trypsin-like activity was enhanced. Here we demonstrate that the Ritonavir-mediated up-regulation of the trypsin-like activity is not affected by specific active site inhibitors of the chymo-trypsin-like and PGPH activity. Moreover, we show that the mutual regulation of chymotrypsin-like and PGPH activities by their substrates as described previously by a "cyclical bite-chew" model is not affected by selective inhibitors of the respective active sites. These data challenge the bite-chew model and suggest that effectors of proteasome activity can act by binding to non-catalytic sites. Accordingly, we propose a kinetic "two-site modifier" model that assumes that the substrate (or effector) may bind to an active site as well as to a second non-catalytic modifier site. This model appears to be valid as it describes the complex kinetic effects of Ritonavir very well. Since Ritonavir partially inhibits major histocompatibility complex class I restricted antigen presentation, the postulated modifier site may be required to coordinate the active centers of the proteasome for the production of class I peptide ligands.
Collapse
Affiliation(s)
- G Schmidtke
- Research Department, Cantonal Hospital St. Gall, CH-9007 St. Gallen, Switzerland
| | | | | | | |
Collapse
|
27
|
Schwarz K, van Den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel PM, Groettrup M. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2000; 165:768-78. [PMID: 10878350 DOI: 10.4049/jimmunol.165.2.768] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The proteasome is a large protease complex that generates most of the peptide ligands of MHC class I molecules either in their final form or in the form of N-terminally extended precursors. Upon the stimulation of cells with IFN-gamma, three constitutively expressed subunits of the 20S proteasome are replaced by the inducible subunits LMP2 (low-molecular mass polypeptide 2), LMP7, and MECL-1 (multicatalytic endopeptidase complex-like-1) to form so-called immunoproteasomes. We show in this study that overexpression of these three subunits in triple transfectants led to a marked enhancement in the H-2Ld-restricted presentation of the immunodominant nonameric epitope NP118, which is derived from the nucleoprotein (NP) of lymphocytic choriomeningitis virus. Overexpression of the alpha and beta subunits of the IFN-gamma-inducible proteasome regulator PA28, in contrast, did not have a comparable effect. In vitro, immunoproteasomes as compared with constitutive proteasomes generated higher amounts of 11- and 12-mer fragments containing the NP118 epitope. These are likely to be cytosolic precursors of NP118, as a proline anchor residue in the second position of NP118 may interfere with TAP-mediated transport of the nonameric epitope itself. In conclusion, we provide evidence that up-regulation of the three inducible subunits, LMP2, LMP7, and MECL-1, can result in a marked improvement of Ag presentation and that, depending on the epitope, PA28 and immunoproteasomes may differentially affect Ag processing.
Collapse
Affiliation(s)
- K Schwarz
- Research Department, Cantonal Hospital St. Gall, St. Gallen, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Schwarz K, Giuli RD, Schmidtke G, Kostka S, van den Broek M, Bo Kim K, Crews CM, Kraft R, Groettrup M. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2000; 164:6147-57. [PMID: 10843664 PMCID: PMC2507740 DOI: 10.4049/jimmunol.164.12.6147] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The complete inhibition of proteasome activities interferes with the production of most MHC class I peptide ligands as well as with cellular proliferation and survival. In this study we have investigated how partial and selective inhibition of the chymotrypsin-like activity of the proteasome by the proteasome inhibitors lactacystin or epoxomicin would affect Ag presentation. At 0.5-1 microM lactacystin, the presentation of the lymphocytic choriomeningitis virus-derived epitopes NP118 and GP33 and the mouse CMV epitope pp89-168 were reduced and were further diminished in a dose-dependent manner with increasing concentrations. Presentation of the lymphocytic choriomeningitis virus-derived epitope GP276, in contrast, was markedly enhanced at low, but abrogated at higher, concentrations of either lactacystin or epoxomicin. The inhibitor-mediated effects were thus epitope specific and did not correlate with the degradation rates of the involved viral proteins. Although neither apoptosis induction nor interference with cellular proliferation was observed at 0.5-1 microM lactacystin in vivo, this concentration was sufficient to alter the fragmentation of polypeptides by the 20S proteasome in vitro. Our results indicate that partial and selective inhibition of proteasome activity in vivo is a valid approach to modulate Ag presentation, with potential applications for the treatment of autoimmune diseases and the prevention of transplant rejection.
Collapse
Affiliation(s)
- Katrin Schwarz
- Research Department, Cantonal Hospital St. Gall, St. Gallen, Switzerland
| | - Rita de Giuli
- Research Department, Cantonal Hospital St. Gall, St. Gallen, Switzerland
| | - Gunter Schmidtke
- Research Department, Cantonal Hospital St. Gall, St. Gallen, Switzerland
| | - Susanne Kostka
- Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany
| | - Maries van den Broek
- Institute of Experimental Immunology, Department of Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Kyung Bo Kim
- Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520
| | - Craig M. Crews
- Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520
| | - Regine Kraft
- Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany
| | - Marcus Groettrup
- Research Department, Cantonal Hospital St. Gall, St. Gallen, Switzerland
- Address correspondence and reprint requests to Dr. Marcus Groettrup, Kantonsspital St. Gallen, Laborforschungsabteilung, Haus 09, CH-9007 St. Gallen, Switzerland. E-mail address:
| |
Collapse
|
29
|
López D, Gil-Torregrosa BC, Bergmann C, Del Val M. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2000; 164:5070-7. [PMID: 10799863 DOI: 10.4049/jimmunol.164.10.5070] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Antigenic peptides derived from viral proteins by multiple proteolytic cleavages are bound by MHC class I molecules and recognized by CTL. Processing predominantly takes place in the cytosol of infected cells by the action of proteasomes. To identify other proteases involved in the endogenous generation of viral epitopes, specifically those derived from proteins routed to the secretory pathway, we investigated presentation of the HIV-1 ENV 10-mer epitope 318RGPGRAFVTI327 (p18) to specific CTL in the presence of diverse protease inhibitors. Both metalloproteinase and proteasome inhibitors decreased CTL recognition of the p18 epitope expressed from either native gp160 or from a chimera based on the hepatitis B virus secretory core protein as carrier protein. Processing of this epitope from both native ENV and the hepatitis B virus secretory core chimeric protein appeared to proceed by a TAP-dependent pathway that involved sequential cleavage by proteasomes and metallo-endopeptidases; however, other protease activities could replace the function of the lactacystin-sensitive proteasomes. By contrast, in a second TAP-independent pathway we detected no contribution of metallopeptidases for processing the ENV epitope from the chimeric protein. These results show that, in the classical TAP-dependent MHC class I pathway, endogenous Ag processing of viral proteins to yield the p18 10-mer epitope requires metallo-endopeptidases in addition to proteasomes.
Collapse
Affiliation(s)
- D López
- Centro Nacional de Biología Fundamental, Instituto de Salud Carlos III, Madrid, Spain
| | | | | | | |
Collapse
|
30
|
Sijts AJ, Standera S, Toes RE, Ruppert T, Beekman NJ, van Veelen PA, Ossendorp FA, Melief CJ, Kloetzel PM. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2000; 164:4500-6. [PMID: 10779750 DOI: 10.4049/jimmunol.164.9.4500] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Proteasomes are the major source for the generation of peptides bound by MHC class I molecules. To study the functional relevance of the IFN-gamma-inducible proteasome subunits low molecular mass protein 2 (LMP2), LMP7, and mouse embryonal cell (MEC) ligand 1 in Ag processing and concomitantly that of immunoproteasomes, we established the tetracycline-regulated mouse cell line MEC217, allowing the titrable formation of immunoproteasomes. Infection of MEC217 cells with Adenovirus type 5 (Ad5) and analysis of Ag presentation with Ad5-specific CTL showed that cells containing immunoproteasomes processed the viral early 1B protein (E1B)-derived epitope E1B192-200 with increased efficiency, thus allowing a faster detection of viral entry in induced cells. Importantly, optimal CTL activation was already achieved at submaximal immunosubunit expression. In contrast, digestion of E1B-polypeptide with purified proteasomes in vitro yielded E1B192-200 at quantities that were proportional to the relative contents of immunosubunits. Our data provide evidence that the IFN-gamma-inducible proteasome subunits, when present at relatively low levels as at initial stages of infection, already increase the efficiency of antigenic peptide generation and thereby enhance MHC class I Ag processing in infected cells.
Collapse
MESH Headings
- Adenoviruses, Human/genetics
- Adenoviruses, Human/immunology
- Adjuvants, Immunologic/physiology
- Amino Acid Sequence
- Animals
- Antigen Presentation/drug effects
- Antigen Presentation/genetics
- Cell Line
- Cysteine Endopeptidases/biosynthesis
- Cysteine Endopeptidases/immunology
- Cysteine Endopeptidases/metabolism
- Cysteine Endopeptidases/physiology
- Dose-Response Relationship, Immunologic
- Enzyme Induction/drug effects
- Enzyme Induction/genetics
- Enzyme Induction/immunology
- Epitopes, T-Lymphocyte/metabolism
- Histocompatibility Antigens Class I/metabolism
- Humans
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Molecular Sequence Data
- Multienzyme Complexes/biosynthesis
- Multienzyme Complexes/immunology
- Multienzyme Complexes/metabolism
- Multienzyme Complexes/physiology
- Peptide Biosynthesis/immunology
- Proteasome Endopeptidase Complex
- T-Lymphocytes, Cytotoxic/enzymology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/metabolism
- T-Lymphocytes, Cytotoxic/virology
- Tetracycline/pharmacology
- Transfection
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- A J Sijts
- Institute of Biochemistry, Charité, Humboldt University, Berlin, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
There are two immune responses in vertebrates: humoral immunity is mediated by circulating antibodies, whereas cytotoxic T lymphocytes (CTL) confer cellular immunity. CTL lyse infected cells upon recognition of cell-surface MHC Class I molecules complexed with foreign peptides. The displayed peptides are produced in the cytosol by degradation of host proteins or proteins from intracellular pathogens that might be present. Proteasomes are cylindrical multisubunit proteases that generate many of the peptides eventually transferred to the cell surface for immune surveillance. In mammalian proteasomes, six active sites face a central chamber. As this chamber is sealed off from the enzyme's surface, there must be mechanisms to promote entry of substrates. Two protein complexes have been found to bind the ends of the proteasome and activate it. One of the activators is the 19 S regulatory complex of the 26 S proteasome; the other activator is '11 S REG' [Dubiel, Pratt, Ferrell and Rechsteiner (1992) J. Biol. Chem. 267, 22369-22377] or 'PA28' [Ma, Slaughter and DeMartino (1992) J. Biol. Chem. 267, 10515-10523]. During the past 7 years, our understanding of the structure of REG molecules has increased significantly, but much less is known about their biological functions. There are three REG subunits, namely alpha, beta and gamma. Recombinant REGalpha forms a ring-shaped heptamer of known crystal structure. 11 S REG is a heteroheptamer of alpha and beta subunits. REGgamma is also presumably a heptameric ring, and it is found in the nuclei of the nematode work Caenorhabditis elegans and higher organisms, where it may couple proteasomes to other nuclear components. REGalpha and REGbeta, which are abundant in vertebrate immune tissues, are located mostly in the cytoplasm. Synthesis of REG alpha and beta subunits is induced by interferon-gamma, and this has led to the prevalent hypothesis that REG alpha/beta hetero-oligomers play an important role in Class I antigen presentation. In the present review we focus on the structural properties of REG molecules and on the evidence that REGalpha/beta functions in the Class I immune response.
Collapse
|
32
|
Sijts AJ, Ruppert T, Rehermann B, Schmidt M, Koszinowski U, Kloetzel PM. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med 2000; 191:503-14. [PMID: 10662796 PMCID: PMC2195811 DOI: 10.1084/jem.191.3.503] [Citation(s) in RCA: 121] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Interferon (IFN)-gamma-induced cells express the proteasome subunits low molecular weight protein (LMP)2, LMP7, and MECL-1 (multicatalytic endopeptidase complex-like 1), leading to the formation of immunoproteasomes. Although these subunits are thought to optimize MHC class I antigen processing, the extent of their role and the mechanistic aspects involved remain unclear. Herein, we study the proteolytic generation of an human histocompatibility leukocyte antigen (HLA)-Aw68-restricted hepatitis B virus core antigen (HBcAg) cytotoxic T lymphocyte (CTL) epitope that is recognized by peripheral blood lymphocytes from patients with acute self-limited but not chronic hepatitis B virus (HBV). Immunological data suggest that IFN-gamma-induced rather than uninduced HeLa cells process and present the HBV CTL epitope upon infection with HBcAg-expressing vaccinia viruses. Analyses of 20S proteasome digests of synthetic polypeptides covering the antigenic HBcAg peptide demonstrate that only immunoproteasomes efficiently perform the cleavages needed for the liberation of this HBV CTL epitope. Although the concerted presence of the three immunosubunits appears essential, we find that both catalytically active LMP7 and inactive LMP7 T1A support CTL epitope generation. We conclude that LMP7 influences the structural features of 20S proteasomes, thereby enhancing the activity of the LMP2 and MECL-1 catalytic sites, which provide cleavage specificity. Thus, LMP7 incorporation is of greater functional importance for the generation of an HBV CTL epitope than cleavage specificity.
Collapse
Affiliation(s)
- Alice J.A.M. Sijts
- From the Institute of Biochemistry, Charité, Humboldt University Berlin, 10117 Berlin, Germany
| | | | - Barbara Rehermann
- Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892
| | - Marion Schmidt
- From the Institute of Biochemistry, Charité, Humboldt University Berlin, 10117 Berlin, Germany
| | | | - Peter-M. Kloetzel
- From the Institute of Biochemistry, Charité, Humboldt University Berlin, 10117 Berlin, Germany
| |
Collapse
|
33
|
Rechsteiner M, Realini C, Ustrell V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J 2000; 345 Pt 1:1-15. [PMID: 10600633 PMCID: PMC1220724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
There are two immune responses in vertebrates: humoral immunity is mediated by circulating antibodies, whereas cytotoxic T lymphocytes (CTL) confer cellular immunity. CTL lyse infected cells upon recognition of cell-surface MHC Class I molecules complexed with foreign peptides. The displayed peptides are produced in the cytosol by degradation of host proteins or proteins from intracellular pathogens that might be present. Proteasomes are cylindrical multisubunit proteases that generate many of the peptides eventually transferred to the cell surface for immune surveillance. In mammalian proteasomes, six active sites face a central chamber. As this chamber is sealed off from the enzyme's surface, there must be mechanisms to promote entry of substrates. Two protein complexes have been found to bind the ends of the proteasome and activate it. One of the activators is the 19 S regulatory complex of the 26 S proteasome; the other activator is '11 S REG' [Dubiel, Pratt, Ferrell and Rechsteiner (1992) J. Biol. Chem. 267, 22369-22377] or 'PA28' [Ma, Slaughter and DeMartino (1992) J. Biol. Chem. 267, 10515-10523]. During the past 7 years, our understanding of the structure of REG molecules has increased significantly, but much less is known about their biological functions. There are three REG subunits, namely alpha, beta and gamma. Recombinant REGalpha forms a ring-shaped heptamer of known crystal structure. 11 S REG is a heteroheptamer of alpha and beta subunits. REGgamma is also presumably a heptameric ring, and it is found in the nuclei of the nematode work Caenorhabditis elegans and higher organisms, where it may couple proteasomes to other nuclear components. REGalpha and REGbeta, which are abundant in vertebrate immune tissues, are located mostly in the cytoplasm. Synthesis of REG alpha and beta subunits is induced by interferon-gamma, and this has led to the prevalent hypothesis that REG alpha/beta hetero-oligomers play an important role in Class I antigen presentation. In the present review we focus on the structural properties of REG molecules and on the evidence that REGalpha/beta functions in the Class I immune response.
Collapse
Affiliation(s)
- M Rechsteiner
- Department of Biochemistry, University of Utah School of Medicine, 50 North Medical Drive, Salt Lake City, UT 84132, USA.
| | | | | |
Collapse
|
34
|
Schmidtke G, Holzhütter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Emch S, Groettrup M. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999; 274:35734-40. [PMID: 10585454 DOI: 10.1074/jbc.274.50.35734] [Citation(s) in RCA: 122] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The human immunodeficiency virus, type I protease inhibitor Ritonavir has been used successfully in AIDS therapy for 4 years. Clinical observations suggested that Ritonavir may exert a direct effect on the immune system unrelated to inhibition of the human immunodeficiency virus, type I protease. In fact, Ritonavir inhibited the major histocompatibility complex class I restricted presentation of several viral antigens at therapeutically relevant concentrations (5 microM). In search of a molecular target we found that Ritonavir inhibited the chymotrypsin-like activity of the proteasome whereas the tryptic activity was enhanced. In this study we kinetically analyzed how Ritonavir modulates proteasome activity and what consequences this has on cellular functions of the proteasome. Ritonavir is a reversible effector of proteasome activity that protected the subunits MB-1 (X) and/or LMP7 from covalent active site modification with the vinyl sulfone inhibitor(125)I-NLVS, suggesting that they are the prime targets for competitive inhibition by Ritonavir. At low concentrations of Ritonavir (5 microM) cells were more sensitive to canavanine but proliferated normally whereas at higher concentrations (50 microM) protein degradation was affected, and the cell cycle was arrested in the G(1)/S phase. Ritonavir thus modulates antigen processing at concentrations at which vital cellular functions of the proteasome are not yet severely impeded. Proteasome modulators may hence qualify as therapeutics for the control of the cytotoxic immune response.
Collapse
Affiliation(s)
- G Schmidtke
- Research Department, Cantonal Hospital St. Gall, CH-9007 St. Gallen, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
35
|
York IA, Goldberg AL, Mo XY, Rock KL. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 1999; 172:49-66. [PMID: 10631936 DOI: 10.1111/j.1600-065x.1999.tb01355.x] [Citation(s) in RCA: 178] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The class I major histocompatibility complex (MHC class I) presents 8-10 residue peptides to cytotoxic T lymphocytes. Most of these antigenic peptides are generated during protein degradation in the cytoplasm and are then transported into the endoplasmic reticulum by the transporter associated with antigen processing (TAP). Several lines of evidence have indicated that the proteasome is the major proteolytic activity responsible for generation of antigenic peptides--probably most conclusive has been the finding that specific inhibitors of the proteasome block antigen presentation. However, other proteases (e.g. the signal peptidase) may also generate some epitopes, particularly those on certain MHC class I alleles. The proteasome is responsible for generating the precise C termini of many presented peptides, and appears to be the only activity in cells that can make this cleavage. In contrast, aminopeptidases in the cytoplasm and endoplasmic reticulum can trim the N terminus of extended peptides to their proper size. Interestingly, the cellular content of proteases involved in the production and destruction of antigenic peptides is modified by interferon-gamma (IFN-gamma) treatment of cells. IFN-gamma induces the expression of three new proteasome beta subunits that are preferentially incorporated into new proteasomes and alter their pattern of peptidase activities. These changes are likely to enhance the yield of peptides with C termini appropriate for MHC binding and have been shown to enhance the presentation of at least some antigens. IFN-gamma also upregulates leucine aminopeptidase, which should promote the removal of N-terminal flanking residues of antigenic peptides. Also, this cytokine downregulates the expression of a metallo-proteinase, thimet oligopeptidase, that actively destroys many antigenic peptides. Thus, IFN-gamma appears to increase the supply of peptides by stimulating their generation and decreasing their destruction. The specificity and content of these various proteases should determine the amount of peptides available for antigen presentation. Also, the efficiency with which a peptide is presented is determined by the protein's half life (e.g. its ubiquitination rate) and the sequences flanking antigenic peptides, which influence the rates of proteolytic cleavage and destruction.
Collapse
Affiliation(s)
- I A York
- Department of Pathology, University of Massachusetts Medical Center, Worcester 01655, USA
| | | | | | | |
Collapse
|
36
|
Gileadi U, Moins-Teisserenc HT, Correa I, Booth BL, Dunbar PR, Sewell AK, Trowsdale J, Phillips RE, Cerundolo V. Generation of an Immunodominant CTL Epitope Is Affected by Proteasome Subunit Composition and Stability of the Antigenic Protein. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.163.11.6045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Generation of the HLA-A0201 (A2) influenza Matrix 58–66 epitope contained within the full-length Matrix protein is impaired in cells lacking the proteasome subunits low molecular protein 2 (LMP2) and LMP7. This Ag presentation block can be relieved by transfecting the wild-type LMP7 cDNA into LMP7-deficient cells. A mutated form of LMP7, lacking the two threonines at the catalytic active site, was equally capable of relieving the block in presentation of the influenza Matrix A2 epitope. These observations were extended by analyzing whether modification of the influenza Matrix protein could overcome the block in presentation of the A2 Matrix epitope. Expression of either a rapidly degraded form of the full-length Matrix protein or shorter Matrix fragments led to an efficient presentation of the A2 influenza Matrix epitope by LMP7-negative cells. These findings demonstrate two main points: 1) LMP7 incorporation into the proteasome is of greater importance for the generation of the influenza A2 Matrix epitope than the presence of the LMP7’s catalytic site; and 2) the interplay between cytosolic proteases and stability of target proteins is of importance in optimization of Ag presentation. These observations may have relevance to the immunodominance of tumor and viral epitopes and raise the possibility that generation of shorter protein fragments could be a mechanism to ensure optimal Ag presentation by cells expressing low levels of LMP7.
Collapse
Affiliation(s)
- Uzi Gileadi
- *Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Hélène T. Moins-Teisserenc
- *Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Isabel Correa
- †Division of Immunology, Department of Pathology, Cambridge, United Kingdom
| | - Bruce L. Booth
- *Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - P. Rod Dunbar
- *Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Andrew K. Sewell
- *Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - John Trowsdale
- †Division of Immunology, Department of Pathology, Cambridge, United Kingdom
| | - Rodney E. Phillips
- *Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Vincenzo Cerundolo
- *Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| |
Collapse
|
37
|
Salzmann U, Kral S, Braun B, Standera S, Schmidt M, Kloetzel PM, Sijts A. Mutational analysis of subunit i beta2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes. FEBS Lett 1999; 454:11-5. [PMID: 10413086 DOI: 10.1016/s0014-5793(99)00768-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Proteasomes are the major protein-degrading complexes in the cytosol and regulate many cellular processes. To examine the functional importance of the MC14/MECL-1 proteasome active site subunits, cell lines expressing a catalytically inactive form of MECL-1 were established. Whereas mutant MECL-1 was readily incorporated into cytosolic proteasomes, replacing the constitutive MC14 subunit, removal of the prosequence was incomplete indicating that its processing required autocatalytic cleavage. Functional analyses showed that the absence of the MC14/MECL-1 active sites abrogated proteasomal trypsin-like activity, but did not affect other catalytic activities. Our data demonstrate a conservation of cleavage specificity between mammalian and yeast proteasomes.
Collapse
Affiliation(s)
- U Salzmann
- Institute of Biochemistry, Charité, Humboldt University Berlin, Germany
| | | | | | | | | | | | | |
Collapse
|
38
|
Sewell AK, Price DA, Teisserenc H, Booth BL, Gileadi U, Flavin FM, Trowsdale J, Phillips RE, Cerundolo V. IFN-γ Exposes a Cryptic Cytotoxic T Lymphocyte Epitope in HIV-1 Reverse Transcriptase. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.162.12.7075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Abstract
The proteasome, an essential component of the ATP-dependent proteolytic pathway in eukaryotic cells, is responsible for the degradation of most cellular proteins and is believed to be the main source of MHC class I-restricted antigenic peptides for presentation to CTL. Inhibition of the proteasome by lactacystin or various peptide aldehydes can result in defective Ag presentation, and the pivotal role of the proteasome in Ag processing has become generally accepted. However, recent reports have challenged this observation. Here we examine the processing requirements of two HLA A*0201-restricted epitopes from HIV-1 reverse transcriptase and find that they are produced by different degradation pathways. Presentation of the C-terminal ILKEPVHGV epitope is impaired in ME275 melanoma cells by treatment with lactacystin, and is independent of expression of the IFN-γ-inducible proteasome β subunits LMP2 and LMP7. In contrast, both lactacystin treatment and expression of LMP7 induce the presentation of the N-terminal VIYQYMDDL epitope. Consistent with these observations we show that up-regulation of LMP7 by IFN-γ enhances presentation of the VIYQYMDDL epitope. Hence interplay between constitutive and IFN-γ-inducible β-subunits of the proteasome can qualitatively influence Ag presentation. These observations may have relevance to the patterns of immunodominance during the natural course of viral infection.
Collapse
Affiliation(s)
- Andrew K. Sewell
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - David A. Price
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Helene Teisserenc
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Bruce L. Booth
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Uzi Gileadi
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Fiona M. Flavin
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - John Trowsdale
- † Division of Immunology, Department of Pathology, Cambridge, United Kingdom
| | - Rodney E. Phillips
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| | - Vincenzo Cerundolo
- *University of Oxford, Nuffield Department of Medicine and Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and
| |
Collapse
|
39
|
Serwold T, Shastri N. Specific Proteolytic Cleavages Limit the Diversity of the Pool of Peptides Available to MHC Class I Molecules in Living Cells. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.162.8.4712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
MHC class I molecules display peptides selected from a poorly characterized pool of peptides available in the endoplasmic reticulum. We analyzed the diversity of peptides available to MHC class I molecules by monitoring the generation of an OVA-derived octapeptide, OVA257–264 (SL8), and its C-terminally extended analog, SL8-I. The poorly antigenic SL8-I could be detected in cell extracts only after its conversion to the readily detectable SL8 with carboxypeptidase Y. Analysis of extracts from cells expressing the minimal precursor Met-SL8-I by this method revealed the presence of SL8/Kb and the extended SL8-I/Kb complexes, indicating that the peptide pool contained both peptides. In contrast, cells expressing full length OVA generated only the SL8/Kb complex, demonstrating that the peptide pool generated from the full length precursor contained only a subset of potential MHC-binding peptides. Deletion analysis revealed that SL8-I was generated only from precursors lacking additional C-terminal flanking residues, suggesting that the generation of the C terminus of the SL8 peptide involves a specific endopeptidase cleavage. To investigate the protease responsible for this cleavage, we tested the effect of different protease inhibitors on the generation of the SL8 and SL8-I peptides. Only the proteasome inhibitors blocked generation of SL8, but not SL8-I. These findings demonstrate that the specificities of the proteases in the Ag-processing pathway, which include but are not limited to the proteasome, limit the diversity of peptides available for binding by MHC class I molecules in the endoplasmic reticulum.
Collapse
Affiliation(s)
- Thomas Serwold
- Division of Immunology, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720
| | - Nilabh Shastri
- Division of Immunology, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720
| |
Collapse
|
40
|
Kloetzel PM, Soza A, Stohwasser R. The role of the proteasome system and the proteasome activator PA28 complex in the cellular immune response. Biol Chem 1999; 380:293-7. [PMID: 10223331 DOI: 10.1515/bc.1999.040] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The generation of antigenic peptides bound and presented to the immune system by MHC class I molecules predominantly depends on the function of the proteasome system. Stimulation of cells with interferon gamma induces the incorporation of three active site bearing beta-subunits into the 20S proteasome and the formation of the PA28 proteasome modulator complex. PA28 alters the cleavage properties of the proteasome and enhances MHC class I antigen presentation. Thus, by cytokine induced change of the proteasome system cells may alter the proteolytic properties of the 20S proteasome and may render an organism more flexible in its peptide generation capacity.
Collapse
Affiliation(s)
- P M Kloetzel
- Institut für Biochemie-Charité, Humboldt-Universität zu Berlin, Germany
| | | | | |
Collapse
|
41
|
Abstract
The principal pathway of antigen processing that is associated with MHC class I involves three main steps: cytosolic peptide generation, peptide transport into the endoplasmic reticulum and peptide assembly with class I molecules. Recent advances suggest that additional cytosolic proteases complement the proteasome as a source of antigenic peptides. Peptide assembly involves several novel cofactors - including the proteins tapasin and ERp57, which may be important for stabilisation of empty class I molecules as well as quality control after peptide binding. Finally, genetic evidence suggests an important influence of an unidentified gene, in the MHC complex, on MHC class I processing.
Collapse
|
42
|
Abstract
Antigen processing by MHC class I molecules begins with the generation of peptides by proteolytic breakdown of proteins. IFN-gamma upregulates gene expression of several proteasomal subunits as well as the proteasome regulator PA28; this implicated their role in antigen degradation. Crystallographic, mutational and biochemical studies contributed to our understanding of the basic principles of proteasomal protein degradation and the consequences of IFN-gamma induction for proteasome function. In addition, nonproteasomal mechanisms seem to be involved in antigen degradation. Leucine aminopeptidase, which is also upregulated by IFN-gamma, was shown to collaborate with the proteasome for epitope production and unknown proteases seem to compensate for the loss of proteasomal degradation in the presence of proteasome inhibitors. Thus, a rather complex picture emerges for the rules governing peptide production in the presence or absence of IFN-gamma.
Collapse
Affiliation(s)
- K Früh
- The R. W. Johnson Pharmaceutical Research Institute, General Atomics Court, San Diego, CA 92121, USA.
| | | |
Collapse
|
43
|
Abstract
The proteasome is the main nonlysosomal endoprotease in the cytoplasm and nucleus of all eukaryotic cells. It is responsible for the generation of most antigenic peptides as ligands for major histocompatibility complex (MHC) class I proteins. The proteasome hence qualifies as a target for modifying or silencing antigen processing and presentation to cytotoxic T cells, which are important players in transplant rejection and autoimmune disease. The authors summarize recent progress in the understanding of antigen processing by the proteasome and discuss the potential of novel and selective proteasome inhibitors as drugs for suppressing or modifying the cytotoxic immune response.
Collapse
|